GlaxoSmithKline PakistanKAR:GLAXO +1.66%92 Current Ratio is 2.43 as of Mar. 2026, which is 36% above its 10-year median of 1.79. GuruFocus rates KAR:GLAXO with a GF Score™ of 92/100 and a GF Value™ of ₨324.26 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 996 Drug Manufacturers companies, GlaxoSmithKline Pakistan ranks better than 58.73% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. GlaxoSmithKline Pakistan's current ratio for the quarter that ended in Mar. 2026 was 2.43.
GlaxoSmithKline Pakistan has a current ratio of 2.43. It generally indicates good short-term financial strength.
The historical rank and industry rank for GlaxoSmithKline Pakistan's Current Ratio or its related term are showing as below:
KAR:GLAXO'
s Current Ratio Range Over the Past 10 Years
Min: 1.51 Med: 1.79 Max: 2.43
Current: 2.43
During the past 13 years, GlaxoSmithKline Pakistan's highest Current Ratio was 2.43. The lowest was 1.51. And the median was 1.79.
KAR:GLAXO's Current Ratio is ranked better than 58.73% of 996
companies
in the Drug Manufacturers industry
Industry Median: 2
vs KAR:GLAXO: 2.43
GlaxoSmithKline Pakistan (KAR:GLAXO) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
GlaxoSmithKline Pakistan Current Ratio Related Terms
GlaxoSmithKline Pakistan Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:GLAXO vs ZTS, UTHR, VTRS: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Current Ratio distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Current Ratio of 2.43 as of Mar. 2026. This is 36% above median its historical median of 1.79. Over the past decade, GlaxoSmithKline Pakistan's Current Ratio has ranged from 1.51 to 2.43. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #411 out of 996 companies in the Drug Manufacturers industry, placing it in the top 41.3%.
Is GlaxoSmithKline Pakistan's Current Ratio too high?
GlaxoSmithKline Pakistan's current Current Ratio of 2.43 is 36% above median its 10-year median of 1.79. Over the past 10 years, this metric has ranged from a low of 1.51 to a high of 2.43. The Drug Manufacturers industry median Current Ratio is 2.00. GlaxoSmithKline Pakistan's value of 2.43 is 21.5% above this industry median. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #411 out of 996 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #411 out of 996 companies for Current Ratio. This puts GlaxoSmithKline Pakistan in the upper half of its industry. The industry median Current Ratio is 2.00. GlaxoSmithKline Pakistan's value of 2.43 is 21.5% above this benchmark. Historically, GlaxoSmithKline Pakistan's own Current Ratio has ranged from 1.51 to 2.43 over the past decade. While the company's 10-year median is 1.79 vs. the industry median of 2.00, GlaxoSmithKline Pakistan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current Current Ratio of 2.43 is 21.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current Current Ratio is 2.43, which is 36% above median its own 10-year median of 1.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.26, compared to a current price of ₨370.25 — trading 14.2% above its estimated fair value. The current Current Ratio is 2.43, which is 36% above median its 10-year median of 1.79 and 21.5% above the Drug Manufacturers industry median of 2.00. GlaxoSmithKline Pakistan's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Current Ratio is 2.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨370.25 is trading 14.2% above its estimated GF Value™ of ₨324.26.
GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.
Key valuation signals for KAR:GLAXO:
Current Ratio: 2.43 (36% above median its 10-year median of 1.79)
GF Value™: ₨324.26 vs. price of ₨370.25 (14.2% above fair value)
Industry Position: 21.5% above the Drug Manufacturers median (#411 of 996)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score
Get the complete analysis for KAR:GLAXO
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
